CDTX - NASDAQ
Cidara Therapeutics, Inc.
$221.38
+0.0000%Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
At a Glance
Live SnapshotCidara Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Cidara Therapeutics, Inc. Cash Flow Statement
CDTX • NASDAQ
| Cidara Therapeutics, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
-169.8M | -22.9M | -33.6M | -42.5M | -72.1M | -41.1M | -59M | -55.7M | -48.2M | -32.2M | -11.9M | -1.3M | -792K | |
233K | 118K | 143K | -1.2M | 229K | 375K | 523K | 667K | 732K | 461K | 179K | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -411K | -3.6M | -33K | -176K | -42K | 0.0 | 0.0 | 0.0 | |
3.9M | 3.1M | 3.5M | 4M | 4.1M | 5.1M | 5.7M | 5.7M | 4.3M | 3M | 232K | 11K | 0.0 | |
3.1M | 1.2M | 982K | 15K | 21K | 36K | 86K | 50K | 14K | 76K | 1.9M | 262K | 792K | |
(95K) | (797K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-13.9M | -3.9M | 454K | 14.4M | 13.4M | 7.5M | -399K | -579K | 3.5M | 2.7M | 1.9M | 23K | 0.0 | |
-176.5M | -22.4M | -28.5M | -25.2M | -54.4M | -28.5M | -56.7M | -49.9M | -39.8M | -26M | -7.7M | -1M | 0.0 | |
INVESTING ACTIVITIES | |||||||||||||
-129K | -505K | -118K | -41K | -186K | -35K | -177K | -306K | -401K | -1.2M | -991K | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -14.5M | -19.5M | -69.6M | -54.9M | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 29M | 24.3M | 95.5M | 10M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.5M | 4.8M | 25.9M | -44.9M | 0.0 | 0.0 | 0.0 | |
-129K | -505K | -118K | -41K | -186K | -35K | (14.3M) | (4.5M) | (25.5M) | -46.1M | -991K | (0.0) | (0.0) | |
FINANCING ACTIVITIES | |||||||||||||
337.3M | 26M | 2.4M | 49M | 40.2M | 14.3M | 6.4M | 20.7M | 26.6M | 69.5M | 0.0 | 0.0 | 0.0 | |
-276K | 0.0 | -2.6M | -4.4M | -3M | 0.0 | 0.0 | 0.0 | 9.9M | 0.0 | 930K | 1.2M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -79K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
7K | 21K | -720K | 6K | 14K | -24K | 49.7M | 228K | 525K | 387K | 516K | 0.0 | 12K | |
337.1M | 26M | -951K | 44.6M | 37.3M | 14.3M | 56.2M | 20.9M | 37.1M | 111.8M | 31.3M | 1.2M | 12K | |
CASH FLOW SUMMARY | |||||||||||||
160.4M | 3M | -29.5M | 19.3M | -17.3M | -14.3M | 13.7M | -24.6M | 22.8M | 39.8M | 22.6M | 184K | 12K | |
35.8M | 32.7M | 62.3M | 42.9M | 60.3M | 74.6M | 60.8M | 85.4M | 62.6M | 22.8M | 185K | 1K | 0.0 | |
196.2M | 35.8M | 32.7M | 62.3M | 42.9M | 60.3M | 74.6M | 60.8M | 85.4M | 62.6M | 22.8M | 185K | 12K | |
-176.7M | -22.9M | -28.6M | -25.3M | -54.6M | -28.6M | -56.9M | -50.2M | -40.2M | -27.1M | -8.7M | -1M | 0.0 |
SEC Filings
CDTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 24, 2025 | September 24, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 25, 2025 | June 24, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 24, 2025 | June 24, 2025 | 2025 |
Related Guides
Continue your CDTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.